Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study. J of Skin. 2020;4(5):s67. doi:10.25251/skin.4.supp.66